Over- and undernutrition: challenges and approaches. 29 June-2 July 2009

Survey of incidence of diverticular disease, dietary advice and probiotic advice in three Surrey practices

J. A. A. Nichols¹ and L. Thomas²

¹60 Manor Way, Onslow Village, Guildford, Surrey GU2 7RR, UK and ²Yakult UK Ltd, Artemis, Odyssey Business Park, West End Road, South Ruislip, Middlesex HA4 6QE, UK

Diverticulosis is a deficiency disease caused by a shortage of dietary fibre⁽¹⁾; 20% of subjects will develop diverticulitis and need antibiotics⁽²⁾. Dietary advice includes increasing intake of vegetable fibre, but giving probiotics during and after antibiotics for a diverticulitis attack may also be beneficial^(3,4). Estimates of the prevalence of diverticulosis based on subjects aged \geq 40 years vary from 6–8% in African countries to 25–50% in European countries^(5,6). In North America the incidence in subjects aged \geq 50 years has been estimated at 40% and 10–25% developed diverticulitis⁽²⁾. According to these studies there is no significant gender bias. However, in the present survey, data derived from UK primary-care electronic records show a lower prevalence of diverticulosis of 11% and the attack rate for diverticulitis per 5 years is two to three times higher in females than males (P<0.001). Although there are more women than men with known diverticulosis, female longevity is a confounding factor. The 7.4% prevalence of diverticulosis in subjects aged \geq 55 years from the general practitioner (GP) records may be an underestimate compared with total population screening for diverticulosis^(5,6).

Results of a questionnaire sent out to patients who had been treated for diverticulitis in the previous 5 years indicated that ≥31% of patients with diverticulitis retained GP advice on dietary fibre and 15.6% recalled being advised to take a probiotic. At the time of completion of the questionnaire 32.5% of subjects were taking a probiotic regularly and further data analysis showed a trend for these subjects to have fewer bowel symptoms and slightly fewer episodes of diverticulitis, which did not reach significance. Several responses to an open-ended comments section seemed to back up this trend: 'Since starting to take a liquid probiotic daily (friend recommendation) frequency & discomfort of attacks has reduced'.

| | То | otal | | Age range (years) | | | | | | | | | | | |
|--|------------------------|------|--------------------|-------------------|--------------------|----|---------------------|----|----------------------|----|----------------------|----|--------------------|-----|--|
| | (all ages) 26 536 565 | | <35 11 197 0 | | 35–44 4217 7 | | 45–54 4093 37 | | 55–64 3285 100 | | 65–74 1891 152 | | >75 1853 269 | | |
| Base (three GP practices) | | | | | | | | | | | | | | | |
| Diverticulosis | | | | | | | | | | | | | | | |
| Diverticulosis by gender | M | F | M | F | M | F | M | F | M | F | M | F | M | F | |
| | 236 | 329 | 0 | 0 | 6 | 1 | 15 | 22 | 45 | 55 | 63 | 89 | 107 | 162 | |
| % all diverticulosis | 42 | 58 | _ | _ | 86 | 14 | 41 | 59 | 45 | 55 | 41 | 59 | 40 | 60 | |
| Diverticulitis in last 5 years % who developed | 115 | | 0 | | 0 | | 12 | | 22 | | 38 | | 43 | | |
| diverticulitis in last 5 years | 20 | | 0 | | 0 | | 32.4 | | 22 | | 25 | | 16 | | |
| Diverticulitis in last 5 years by gender and age | M | F | M | F | M | F | M | F | M | F | M | F | M | F | |
| | 30 | 85 | 0 | 0 | 0 | 0 | 2 | 10 | 5 | 17 | 13 | 25 | 10 | 33 | |
| % all diverticulitis in diverticulitis age-group | 26 | 74 | _ | _ | _ | _ | 17 | 83 | 23 | 77 | 34 | 66 | 23 | 77 | |

M, male; F, female

Patients who stay on a long-term daily probiotic regimen appear to have fewer attacks of diverticulitis but the power of this retrospective survey was inadequate to test the hypothesis that probiotics are genuinely beneficial. A larger prospective trial is needed and it is suggested that subjects should be recruited who have had two or more episodes of diverticulitis. An open label pilot study of a daily dose of a probiotic for 2 years could be the next stage but ultimately a randomised control trial of probiotic ν , a placebo will be essential.

- 1. Santhini J & Savvas P (2008) Int J Colorectal Dis 23, 619-627.
- 2. Parks TG (1975) Clin Gastroenterol 4, 53-69.
- 3. Giaccari S, Tronci S, Falconieri M et al. (1993) Riv Eur Sci Med Farmacol 15, 29–34.
- 4. Fric P & Zavarol M (2003) Eur J Gastroenterol Hepatol 15, 313-315.
- 5. Blachut K, Paradowski L & Garcarek J (2004) Rom J Gastroenterol 13, 281–285.
- 6. Hughes LÉ (1969) Gut 10, 336-351.